GleamWall
中文EN

GUTS FRACTYL HEALTH, INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1572616 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-22.5%
TTM net income YoY10.9%
TTM EPS YoY96.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin46.2%
Operating margin-100,571.0%
Net margin-73,864.5%
FCF margin-72,350.5%
EBITDA margin-99,843.0%

Returns

ROE—
ROA-74.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets73.7%
Debt / equity0.00x
Current ratio3.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue1,897.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$3,000
Cost of revenue———————$0
Gross profit———————$3,000
R&D expense$12.45M$13.81M$15.60M$16.49M$17.46M$21.15M$19.43M$20.28M
SG&A expense$6.20M$5.28M$5.22M$6.79M$5.24M$4.93M$5.32M$4.93M
Operating income-$18.65M-$19.10M-$20.82M-$23.28M-$22.69M-$26.08M-$24.76M-$25.21M
Net income-$14.15M-$25.54M$9.22M-$43.73M-$45.60M-$27.89M-$23.73M-$24.97M
EBITDA-$18.37M-$18.82M-$20.54M-$23.00M-$22.40M-$25.81M-$24.47M-$24.99M
EPS (basic)-1.07-0.160.06—-8.46-0.57-0.49—
EPS (diluted)-1.07-0.160.06—-8.46-0.57-0.49—
Weighted avg. shares (diluted)13.25M158.65M158.49M—5.39M49.04M48.87M—
Balance sheet
Cash & equivalents$31.52M$47.14M$63.17M$81.54M$81.91M$26.55M$46.36M$71.72M
Receivables———————$0
Inventory———————$73,000
Current assets$34.33M$49.60M$65.92M$87.58M$79.70M$26.69M$47.05M$71.76M
PP&E, net$1.69M$1.85M$2.13M$2.41M$2.68M$2.96M$3.14M$2.98M
Total assets$65.92M$81.98M$99.39M$121.40M$114.27M$62.01M$83.04M$108.08M
Current liabilities$17.34M$15.74M$15.41M$18.33M$18.68M$21.83M$18.80M$19.77M
Total liabilities$79.14M$83.64M$78.01M$111.94M$117.45M$80.22M$76.67M$79.65M
Shareholders' equity-$13.22M-$1.67M$21.38M$9.46M-$3.18M-$18.21M$6.38M$28.42M
Shares outstanding13.26M158.65M158.65M12.78M132.22M49.92M48.92M48.76M
Cash flow statement
Operating cash flow-$15.71M-$15.90M-$22.48M-$21.34M-$22.71M-$21.20M-$25.08M-$17.03M
Capital expenditure———$3,000$8,000$98,000$448,000$233,000
Free cash flow———-$21.34M-$22.72M-$21.30M-$25.53M-$17.27M
Investing cash flow———-$3,000-$8,000-$98,000-$448,000-$233,000
Financing cash flow$83,000-$127,000$4.11M$25.22M$78.09M$1.48M$171,000$67,000
Depreciation & amortization$276,000$278,000$281,000$279,000$290,000$270,000$290,000$223,000
Stock-based compensation$2.39M$2.50M$2.53M$1.85M$1.64M$1.78M$1.41M$2.90M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.